Key Points {#FPar1}
==========

This review provides an evaluation of the effectiveness and safety of currently available medicines when taken with medicines used to control stomach acid.For medications found to have meaningful interactions, ways of avoiding or reducing the effect of the acid-controlling medication are suggested.Medicines that are not affected by gastric-acid controllers are also identified so prescribers and patients know they do not have to be concerned about altered effectiveness or safety when using them with gastric acid controllers.

Introduction {#Sec1}
============

Gastric acid-reducing agents (ARAs) are commonly used among patients across all fields of medicine and are often recommended to treat conditions related to gastrointestinal disease \[[@CR1], [@CR2]\]. Because of the frequent use of ARAs, the potential for drug--drug interactions (DDIs) is an important consideration. The three ARA classes on the market include antacids, histamine H~2~ receptor antagonists (H2RAs), and proton pump inhibitors (PPIs). These medication classes raise gastric pH through different mechanisms and with different durations of action: antacids are short acting, H2RAs are intermediate acting, and PPIs are long acting \[[@CR3], [@CR4]\]. The H2RA and PPI classes each include agents that differ in their interaction potential via cytochrome P450 (CYP) enzymes and active transporters, which could potentially affect the metabolism and/or excretion of other concurrently administered medications \[[@CR5], [@CR6]\]. However, each of these classes share the potential to interact through increased gastric pH, which may affect concurrently administered drugs with pH-dependent solubility, pH-dependent stability, or pH-sensitive release from a dosage form by influencing the rate and/or extent of absorption \[[@CR5]\].

Most ARAs are available over the counter, which can be potentially problematic in terms of DDIs, especially in patients who are taking many concurrent medications without medical supervision of their ARA use \[[@CR7], [@CR8]\]. Polypharmacy, generally referring to the concurrent use of five or more medications, drastically increases the risk of DDIs. To ameliorate the challenge polypharmacy poses, prescribers and pharmacists often conduct comprehensive medication reviews, including non-prescription medications, and then counsel the patient on their medications and warn them of any adverse effects or potential drug interactions and how to mitigate them \[[@CR7]\].

A comprehensive review of gastric acid-mediated DDIs using ARAs as the perpetrator might aid in the treatment of patients with polypharmacy and potentially avoid drug interactions that would otherwise affect their care. By further identifying the specific mechanism of interaction, possible mitigation strategies and alternative options can be chosen by the prescriber. This comprehensive review could save time for prescribers and pharmacists who are responsible for the care of many patients by providing a reference to help screen for ARA-mediated DDIs. In addition, this systematic review provides mitigation strategies for ARA-mediated DDIs.

Although several review articles have been published discussing gastric acid-related DDIs mediated by coadministration of antacids \[[@CR1]\], H~2~RAs \[[@CR9]\], or PPIs \[[@CR2], [@CR10]--[@CR12]\], these reviews are not sufficiently comprehensive in capturing all documented DDIs with ARAs and tend to focus on gastric pH-dependent DDIs and/or basic drugs. Subsequently, several new drugs have been approved, and new information is available in the literature. Thus, the objective of this systematic review is to comprehensively identify oral medications with clinically meaningful DDIs, including loss of efficacy or adverse effects with ARAs, and to categorize these medications according to mechanism of interaction.

Factors for Drug Disposition {#Sec2}
============================

ARAs may act as perpetrators (i.e., drugs that cause or are believed to have an effect on the substrate drug) with substrate medications (i.e., drugs whose systemic exposure may or may not be changed by a perpetrator drug) by affecting their absorption, metabolism, or elimination, and these mechanisms are discussed in this section.

Absorption {#Sec3}
----------

Following oral administration, medications typically are systemically absorbed through the gastrointestinal tract into the bloodstream to allow distribution to the target site(s) of action \[[@CR13], [@CR14]\]. The extent and rate of absorption is determined by both the properties of the medication and the gastrointestinal characteristics of the individual patient (e.g., food status, comedications, gastrointestinal disease, etc.). The intrinsic physicochemical properties of the medication are important factors for oral absorption, including stability, solubility, permeability, lipophilicity, particle size, shape and physical form of the active pharmaceutical ingredient, and formulation \[[@CR15], [@CR16]\].

To fully understand DDIs mediated by ARAs through increased gastric pH, it is important to review physiologic gastrointestinal pH. The range of pH varies widely in the human digestive tract. In the fasting state, the lower stomach secretes hydrochloric acid until it reaches a pH of 1.0--3.5, and a pH of 3.0--7 when in a fed state. The pH in the small intestine is 6.0--8.0, and in the colon the pH is 5.5--8.0 \[[@CR14], [@CR17], [@CR18]\].

### Weak Acids and Weak Bases {#Sec4}

When gastric pH is raised by ARAs, the solubility of weak acids generally increases \[[@CR19]\]. For clinical doses of weakly acidic drugs that are not completely dissolved in gastric fluid at physiologic pH, an increase in gastric pH may lead to an increased dissolution and likewise subsequent absorption rate and/or extent. For clinical doses of weakly basic drugs that are not completely dissolved at physiologic pH, an increase in gastric pH would result in a decrease in dissolution and also subsequent absorption rate and/or extent \[[@CR19]\]. Most clinically meaningful DDIs caused by ARAs through this mechanism are with weak bases.

### Formulation/Dosage Form Effect {#Sec5}

There are many different formulations of oral dosage forms available on the market \[[@CR20]\]. These include immediate-release (IR) dosage forms and modified-release (MR) dosage forms.

#### Modified-Release Dosage Forms {#Sec6}

MR dosage forms, often introduced to reduce dosing frequency \[[@CR20]\], include extended-release (ER) and delayed-release (DR) forms. Examples of these ER dosage forms include controlled-release, sustained-release, timed-release, and long-acting forms. These ER dosage forms do not commonly interact with ARAs because of a lack of involvement of a pH component in drug release.

DR dosage forms include enteric-coated products, which pass through the stomach unaltered and are then triggered to release by the higher pH environment of the lower gastrointestinal tract \[[@CR20]\]. DR dosage forms protect the drug from gastric fluids, reduce gastric irritation by the drug, and improve drug absorption in the desired location of the gastrointestinal tract. Enteric coatings are beneficial particularly in regard to drugs with chemical or physical instability in acidic conditions. For those medications designed to not release in the stomach, the pH of release can range from 5.0 to 7.0, depending on the intended location in the gut \[[@CR21]\]. Notably, ARAs can raise gastric pH above 6.0 \[[@CR22]\], which can lead to premature release of drug formulated in a DR dosage form. The implications of this are potential degradation of the drug in gastric fluid, gastric irritation by the drug, and altered absorption rate and/or extent \[[@CR23]\]. DR dosage forms are most likely to interact with ARAs because of the inherent pH-related release profile. However, some DR formulations, such as time-based dosage forms, are independent of pH.

#### Immediate-Release Dosage Formulations {#Sec7}

IR dosage forms dissolve rapidly after oral administration. For these formulations, the acid--base characteristics of the substrate medication are important in determining its solubility and/or its chemical stability in gastric fluid \[[@CR1]\]. ARAs have the potential to interact with IR formulations when a substrate medication exhibits pH-dependent solubility or pH-dependent chemical stability.

### Chelation {#Sec8}

Polyvalent cations in antacid formulations may form an insoluble chelate complex with medications \[[@CR1]\]. Such chelates may be poorly absorbed, reducing bioavailability of the substrate medication. Chelation requires a net cation charge of + 2 or + 3; thus, calcium-, magnesium-, and aluminum-containing antacids are common culprits in regard to chelating effects with substrate medications. Sodium bicarbonate, the only metal ion-containing antacid with a net charge of + 1, is not subject to chelation-based DDIs \[[@CR24]\].

Metabolism {#Sec9}
----------

### Cytochrome P450 {#Sec10}

CYP is a heme-containing superfamily responsible for the biotransformation of exogenous substances, including \~ 80% of medications \[[@CR25]\]. With respect to ARAs, CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 are the most important from a DDI standpoint. CYP1A2 is predominantly expressed in the liver and is responsible for the metabolism of medications such as clozapine, olanzapine, theophylline, and derivatives thereof \[[@CR25], [@CR26]\]. Among the CYP2 enzymes, CYP2C9 is the most abundantly expressed CYP2 enzyme in the liver, accounting for the metabolism of \~ 20% of medications \[[@CR26]\]. Because of the polymorphic potential of CYP2C9, variation in the metabolism and disposition of drugs is evident between individuals, which can be problematic for those drugs with a narrow therapeutic index \[[@CR25], [@CR26]\]. CYP2C19 is a clinically important enzyme that metabolizes several drugs, including omeprazole, diazepam, and propranolol \[[@CR25]--[@CR27]\]. Many clinically relevant interactions of ARAs with CYP-metabolized drugs occur via CYP2C19 \[[@CR25]\]. The enzyme CYP2D6 is responsible for the metabolism of \~ 20% of medications \[[@CR25], [@CR26]\]. CYP3A4 is one of the major CYP3A enzymes in humans, which are involved in the metabolism of a wide range of substrate types and are, in fact, responsible for the metabolism of \~ 30 to 50% of medications \[[@CR25], [@CR26]\].

H2RAs and PPIs have the potential to act either as inhibitors or inducers of CYP enzymes \[[@CR5]\]. When acting as an inhibitor of CYP, concomitant administration of an ARA may result in increased systemic exposure of a drug or decreased conversion of a prodrug to its active form. In fact, inhibition of CYP represents a common cause of DDIs seen in clinical practice \[[@CR28]\]. Such inhibition of CYPs by H2RAs and PPIs occurs via reversible competitive inhibition, where the substrate medication and ARA (or inhibitor) both bind to the active site of the enzyme. The degree of inhibition depends on the concentration of the ARA at the active site, and the 'CYP profiles' of both the substrate medication and ARA \[[@CR2]\].

In contrast to CYP inhibition, induction of CYP enzymes may occur, resulting in either increased activity of a prodrug or heightened elimination of the drug itself. Inducible enzymes include CYP2A, CYP2B, CYP2C, CYP2E, and CYP3A \[[@CR29]\]. Notably, ARA-mediated CYP induction is less commonly seen with respect to clinically meaningful DDIs.

Elimination {#Sec11}
-----------

### Organic Cation Transporter 2 {#Sec12}

Organic cation transporters (OCTs) are expressed throughout the body; however, OCT2 is primarily localized in the proximal tubule of the kidney. OCTs work in tandem with efflux transporters to aid in drug excretion \[[@CR6]\]. For example, OCTs function to secrete endogenous cations and remove positively charged drugs (e.g., ranitidine) from the body. On the basis of in vitro data, OCT2 can be inhibited by H2RAs, which may lead to decreased renal excretion of substrate medication and increased systemic exposure and potential toxicity \[[@CR6]\].

### *P*-Glycoprotein {#Sec13}

*P*-Glycoprotein (P-gp), also known as multidrug resistance protein 1, is important for drug transport, aiding in the movement of the medication from the intestinal mucosa back into the gut lumen, thus contributing to first-pass elimination \[[@CR30]\]. Intuitively, inhibition of this transporter would mean a medication would be absorbed to a higher degree, potentially leading to adverse effects possibly associated with attainment of toxic plasma concentrations of medications even when given at recommended doses.

### Urine Alkalization {#Sec14}

Antacids have the potential to increase urinary pH \[[@CR1]\]. In a study of healthy men, increases in urine pH of 0.48 and 0.86 U were observed with administration of magnesium hydroxide and aluminum and magnesium hydroxide suspension, respectively, over a 7-day period \[[@CR31]\]. Urinary pH can be a major factor for the renal excretion of medications. In alkaline urine, the renal clearance of weakly acidic drug molecules will tend to be increased. In an alkaline environment, weakly acidic drugs are polar (charged), and thus are less likely to pass through membranes for reabsorption into the systemic circulation, and weakly basic drugs will be rendered neutral and remain non-polar (uncharged), allowing them to be more likely to pass through membranes to re-enter the systemic circulation and increase their systemic exposure \[[@CR32]\]. Increased urinary pH may lead to either toxic concentrations being reached for weakly basic drug molecules or reduced efficacy for weakly acidic drug molecules.

Implications {#Sec15}
------------

Therapeutic doses of ARAs can raise the gastric pH to \> 6.0 \[[@CR19]\]. It is important to differentiate the mechanism by which different ARAs work and the degree to which they affect gastric pH. In addition, it is important to identify other possible mechanisms of interaction between ARAs and substrate medications. By understanding such mechanisms, possible mitigation strategies can be investigated. Currently, common mitigation strategies include spacing of the dosing interval, avoidance of interaction, choosing an alternative agent, or monitoring of therapy \[[@CR1], [@CR2], [@CR9]\].

Types of Gastric Acid-Reducing Agents and their Mechanisms of Interaction {#Sec16}
=========================================================================

Antacids {#Sec17}
--------

Antacids consist of basic substances coupled with a cation \[[@CR1]\]. Antacids directly neutralize gastric acid, providing a quick onset of action and a short duration of acid suppression of \~ 2 h due to gastric emptying and gastric acid secretion. The most commonly available over-the-counter antacids are sodium bicarbonate, calcium carbonate, aluminum hydroxide, and magnesium hydroxide (Table [1](#Tab1){ref-type="table"}). The possible mechanisms underlying DDIs for antacids are discussed in Sects. [3.1.1](#Sec18){ref-type="sec"}--[3.1.4](#Sec21){ref-type="sec"}.Table 1Clinically meaningful acid-reducing agent drug interaction potential and metabolic pathwaysDrugAbsorptionMetabolism via CYP systemTransport systemsExcretionGastric pH-dependent interactionChelationCYP1A2CYP2A6CYP2C9CYP2C19CYP2D6CYP3A4OCT2^a^P-gp^a^Urine alkalizationAntacid Sodium bicarbonate✓✓ Calcium carbonate✓✓✓ Aluminum hydroxide✓✓✓ Magnesium hydroxide✓✓✓H2RA Cimetidine✓xxxxx Ranitidine✓sssx Famotidine✓x Nizatidine✓PPI Omeprazole✓issx, S′ssx Esomeprazole✓x, S′s Lansoprazole✓isssx Dexlansoprazole✓ss Pantoprazole✓S′sx Rabeprazole✓S′S′*ARA* acid-reducing agent, *CYP* cytochrome P450, *H2RA* histamine H~2~ receptor antagonist, *I* inducer, *OCT2* organic cation transporter 2, *P*-*gp* P-glycoprotein, *PPI* proton pump inhibitor, *s* minor substrate, *S*′ major substrate, *x* inhibitor, ✓ elicits pathway^a^In vitro evidence only for OCT2 and P-gp

### Gastric pH Elevation {#Sec18}

Neutralization of gastric fluid by antacids may alter the dissolution, absorption, stability, or release of dosage forms of substrate medications \[[@CR1]\]. However, the short duration of gastric pH elevation by antacids allows for the potential mitigation strategy of separation of doses apart in time of the antacid and substrate medication.

### Chelation {#Sec19}

Sodium bicarbonate is the only antacid containing a metal ion that is not known to chelate with substrate medications (Sect. [2.1.3](#Sec8){ref-type="sec"}) \[[@CR24]\]. Accordingly, sodium bicarbonate can be used as an alternative antacid therapy over therapies containing magnesium and/or aluminum, metal ions that chelate with substrate medications. Again, separation of doses in time is a possible mitigation strategy to avoid chelation-based drug interactions. In addition, it is possible to switch to an H2RA or PPI to avoid such interactions, obviously as long as there is no new potential interaction.

### Gastrointestinal Motility {#Sec20}

Magnesium-containing antacids may promote gastric emptying and accelerate the rate of absorption of some drugs \[[@CR1]\]. The clinical relevance of this is unclear. Notably, formulations containing magnesium alone are no longer used as antacids essentially because of the adverse effect of diarrhea. Combination products containing both magnesium and aluminum are now more common; aluminum counteracts the increase in gastric emptying observed with magnesium alone.

### Alkalization of Urine {#Sec21}

Since antacids are basic compounds, they have the potential to alkalize urine, altering the renal excretion of weakly acidic and weakly basic medications \[[@CR32]\]. Possible mitigation strategies proposed in the prescribing information include selection of an alternative ARA (H2RA or PPI), monitoring for increased or decreased effects of substrate medication, and possible dose adjustment of the substrate medication. In this case, separation of dosing in time is less likely to be a successful mitigation strategy; however, this has not been well-studied.

Histamine H~2~ Receptor Antagonists {#Sec22}
-----------------------------------

Commonly used H2RAs available over the counter include cimetidine, ranitidine, nizatidine, and famotidine \[[@CR9], [@CR33], [@CR34]\]. H2RAs compete reversibly with histamine at H~2~ receptors in gastric parietal cells to reduce gastric acid secretion. Potential for DDIs with H2RAs should be considered in the context of their pharmacokinetic profile, which drives the effect on gastric pH, with a peak effect at 2 h and a duration of action of up to 12 h \[[@CR35]\]. The possible mechanisms underlying putative DDIs with H2RAs are discussed in Sects. [3.2.1](#Sec23){ref-type="sec"}--[3.2.3](#Sec25){ref-type="sec"}.

### Gastric pH Elevation {#Sec23}

Various mitigation strategies have been proposed, including avoidance of the H2RA, administering the substrate at least 2 h before the H2RA, dosing the substrate and H2RA simultaneously, and administering the substrate medication 10--12 h after the H2RA \[[@CR19], [@CR35]\]. When considering these mitigation strategies, thought must be given to the pharmacokinetics of the substrate medication and extent of the effect of increased gastric pH on the substrate medication.

### The Cytochrome P450 Enzyme System {#Sec24}

H2RAs have the potential to interact with substrate medications that undergo CYP enzyme metabolism \[[@CR5]\]. H2RAs can inhibit CYP enzymes, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Cimetidine, the first approved H2RA, is an inhibitor of multiple CYP enzymes; however, newer H2RAs have less effect on CYP metabolism. For example, ranitidine is not as potent of a CYP inhibitor as cimetidine, and famotidine has a negligible effect on CYP enzymes \[[@CR5]\].

Possible mitigation strategies when a clinically meaningful CYP-based interaction is seen with H2RAs include avoidance, monitoring for increased or decreased effects and possible dose adjustment of the substrate medication, or selection of an alternative ARA or substrate medication.

### Organic Cation Transporter 2 {#Sec25}

H2RAs have the potential to inhibit OCT2, which is the most clinically relevant of the OCTs for H2RA-mediated DDIs \[[@CR6]\]. Possible mitigation strategies when a clinically meaningful OCT2-based interaction is seen with H2RAs include avoidance, monitoring for increased or decreased effects and possible dose adjustment of the substrate medication, or selection of alternative ARA or substrate medication.

Proton Pump Inhibitors {#Sec26}
----------------------

Common PPIs include omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole, with many of these being available without a prescription \[[@CR2], [@CR10]--[@CR12], [@CR36]--[@CR38]\]. PPIs irreversibly bind and inactivate the proton pump (i.e., the hydrogen/potassium adenosine triphosphatase system) at the secretory surface of gastric parietal cells. This results in suppression of gastric acid production for \> 24 h, but 4 days of repeated dosing is required to reach maximal effect. Similar efficacy has been shown in acid suppression studies comparing omeprazole, lansoprazole, rabeprazole, and pantoprazole \[[@CR4]\]. Esomeprazole has a stronger degree of acid suppression, with a longer period of intragastric pH \> 4. However, the gastric pH-dependent interaction is class specific and does not appear to be markedly different among individual PPIs \[[@CR4], [@CR36]\]. The multiple possible DDI mechanisms of PPIs are discussed in Sects. [3.3.1](#Sec27){ref-type="sec"}--[3.3.3](#Sec29){ref-type="sec"}.

### Gastric pH Elevation {#Sec27}

In contrast to other ARAs, the duration of raised gastric pH is sustained over the dose interval for PPIs. Therefore, there are fewer options for mitigation strategies for PPIs compared with antacids and H2RAs. The possible mitigation strategies for gastric pH elevation caused by PPIs include avoidance of the PPI, monitoring for increased or decreased effects of substrate medication, and setting a maximum dose of the PPI.

### The Cytochrome P450 Enzyme System {#Sec28}

PPIs can affect CYP2C19 and CYP1A2 activity \[[@CR2], [@CR11], [@CR12], [@CR38]\]. Omeprazole and esomeprazole reversibly inhibit CYP2C19 to a clinically meaningful degree, whereas other marketed PPIs inhibit CYP2C19 but not to a degree that is clinically relevant \[[@CR39]--[@CR41]\]. Omeprazole has been shown to clinically induce the activity of CYP1A2 in some studies but not others \[[@CR2]\]. Possible mitigation strategies for CYP-mediated drug interactions with PPIs include avoidance of the PPI, monitoring for increased or decreased effect with possible dose reduction of substrate medication, or immediate dose reduction of substrate medication upon initiation of the PPI. While separation of dosing in time is sometimes an option for PPIs when a gastric pH--dependent mechanism is suspected, it is not recommended for CYP-only-based interactions.

### *P*-Glycoprotein Efflux Transporter {#Sec29}

It is unknown if clinically meaningful DDIs with PPIs are mediated through P-gp. One in vitro study concluded that omeprazole, lansoprazole, and pantoprazole are substrates and inhibitors of P-gp, but with only moderate potency \[[@CR38]\].

Comprehensive Review of Gastric Acid-Reducing Agent-Mediated Drug--Drug Interactions {#Sec30}
====================================================================================

Methods {#Sec31}
-------

This review is a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009-guided systematic review to identify oral medications that were substrates of an interaction with ARAs/perpetrators \[[@CR42]\]. To conduct these analyses, four commercially available databases were used.

The initial search strategy was completed using the PDR3D: Reed Tech Navigator™ for Drug Labels, which is a database of prescribing information from a broad range of countries/regions. The 30 terms in Table [2](#Tab2){ref-type="table"} include generic names of antacids, H2RAs, and PPIs, as well as three common brands of combination antacid products. The first 27 terms listed in Table [2](#Tab2){ref-type="table"} were each searched in the "clinical pharmacology" and "drug interaction" sections of the prescribing information available through the database using the "OR" function. The last three terms in Table [2](#Tab2){ref-type="table"} related to dosage forms searched in "all" sections of the prescribing information. The PDR3D database was searched during the period of 1 June 2018--1 August 2018.Table 2PDR3D: Reed Tech Navigator™ and DailyMed search termsPPIGastric acidProton pump inhibitorGastric pHOmeprazolepH dependentEsomeprazoleChelationLansoprazoleAntacidsDexlansoprazoleSodium bicarbonatePantoprazoleCalcium carbonateRabeprazoleAluminum hydroxideH2 antagonistsMagnesium hydroxideH2 blockersMaalox^a^CimetidineRiopan^b^RanitidineGaviscon^c^FamotidineEnteric coatedNizatidineDelayed releaseAcid-reducingModified release*PPI* proton pump inhibitor^a^Maalox^®^. Aluminum hydroxide 225 mg, magnesium hydroxide 200 mg^b^Riopan^®^. Magaldrate oral suspension^c^Gaviscon^®^. Aluminum hydroxide and magnesium carbonate suspension

The University of Washington Drug--Drug Interaction Database (DIDB) was also searched from 15 June 2018 to 26 July 2018. The DIDB has the largest manually curated collection of in vitro and in vivo data related to drug interactions in humans primarily based on scientific literature. A query was created for the term "precipitant," which by the University of Washington database definition is the equivalent of a perpetrator. Each term in Table [3](#Tab3){ref-type="table"} was searched individually as a "precipitant" and specified for "in vivo" results only. Medications under all categories were evaluated for interactions, as follows: the query "in vivo no mechanism" aided in identifying substrates that do not interact with ARAs or do not have an interaction that is clinically meaningful, the query "in vivo other mechanism \> 20%" aided in identifying substrates reported to have a gastric pH-based interaction with ARAs, the queries "in vivo no inhibition" and "in vivo no induction" covered any medications considered to be gastric pH based but not included in the "in vivo other mechanism \> 20%" group, and the queries "in vivo induction \> 20%" and "in vivo inhibition \> 20%" covered medications that interacted via metabolic enzymes and transporters. Citations were provided to the prescribing information for the medication available at the Drugs\@FDA webpage and/or PubMed publications evaluating the interaction.Table 3University of Washington Drug--Drug Interaction database search termsOmeprazoleNizatidineEsomeprazoleSodium bicarbonateLansoprazoleCalcium carbonateDexlansoprazoleAluminum hydroxidePantoprazoleMagnesium hydroxideRabeprazoleMaalox^a^CimetidineRiopan^b^RanitidineGaviscon^c^Famotidine^a^Maalox^®^. Aluminum hydroxide 225 mg, magnesium hydroxide 200 mg^b^Riopan^®^. Magaldrate oral suspension^c^Gaviscon^®^. Aluminum hydroxide and magnesium carbonate suspension

Pharmaceutical companies with approved medications for marketing in the USA are required to have up-to-date prescribing information available to the public, and the DailyMed database contains this information. The search strategy used for PDR3D (see earlier in this section) was replicated for the DailyMed database from 28 June 2018 to 1 August 2018 (Table [2](#Tab2){ref-type="table"}).

The information collected from each database was organized on the basis of the presence or absence of a clinically meaningful interaction. For medications exhibiting an interaction, the substrate drug name, ARA (perpetrator), clinical effect on substrate drug, mechanism of interaction, evidence of interaction (clinical data), and intervention strategy were complied. For medications without an interaction, the medication name, concurrent ARA name, directions of use, and clinical data supporting the lack of a clinically meaningful interaction were also compiled.

Throughout the search strategy described earlier, repeat medications, names of ARA products (omeprazole, ranitidine, Maalox^®^, etc.), non-oral dosage forms, and medications with no basis for a pharmacokinetic interaction were removed. The remaining medications were then evaluated to determine whether the drug was a substrate or a perpetrator, and perpetrators were removed. Potential substrates were subsequently evaluated for a clinically meaningful interaction or no interaction/no clinically meaningful interaction. A clinically meaningful interaction was defined as when the prescribing information recommended some intervention for either the perpetrator or substrate as a result of the interaction (e.g., spacing, avoidance, or change in dose). If a pharmacokinetic interaction was observed, but no action was recommended by the prescribing information, this was considered to be a non-clinically meaningful interaction. Substrates with clinically meaningful interactions were further evaluated for description of the mechanism(s) of interaction, which were typically claimed in the prescribing information; however, for the few medications that did not claim a probable mechanism in the label, PubMed was used to try to determine the mechanism. The greatest emphasis was placed on the prescribing information, while case reports were not considered a definitive source for an associated interaction. If there was conflicting evidence presented between databases, the UpToDate^®^/Lexicomp^®^ Drug and Drug Interaction screening tool was used to resolve this.

The UpToDate^®^/Lexicomp^®^ screening tool uses scientific literature and prescribing information to provide peer-reviewed clinical practice advice to healthcare professionals when different databases present conflicting evidence for the presence or absence of a clinically meaningful interaction for a particular medication pair. Conflicting evidence appeared \~ 10% of the time, mostly for interactions considered to be non-gastric pH based. This was resolved by using a decision-making sequence. First, the prescribing information was referenced for evidence of an interaction; if there was no evidence for a clinically meaningful interaction and scientific literature (PubMed) presented conflicting evidence for a potential interaction, the UpToDate^®^/Lexicomp^®^ screening tool was used to evaluate current clinical practice along with any supporting information. In addition, this tool was used to cross-reference the interactions identified through PDR3D, the University of Washington DIDB, and/or DailyMed. This screening tool was used from 28 June 2018 to 1 August 2018.

Results {#Sec32}
-------

Figure [1](#Fig1){ref-type="fig"} describes the PRISMA-compliant flow diagram of the search strategy conducted and the output that was further analyzed. 'Identification' used PDR3D, University of Washington DIDB, and DailyMed to compile a list of medications to be screened for an interaction with ARAs. 'Screening' allowed for the removal of repeat medications, names of ARA products, non-oral dosage forms, and medications not relevant to an interaction with ARAs. 'Eligibility' allowed for identification of medications to be potential substrates or perpetrators, with perpetrators being removed. Potential substrates were then analyzed for the presence or absence of a clinically meaningful interaction. Substrates with a clinically meaningful interaction were distinguished on the basis of their mechanism of interaction (gastric pH based or non-gastric pH based).Fig. 1Preferred reporting items for systematic reviews and meta-analyses (PRISMA)-compliant methods output diagram. ^a^'Other' means mediated by CYP, transporter, chelation, urine alkalization, etc. *ARA* acid-reducing agent, *DDI* drug--drug interaction

Medications with a gastric pH-dependent mechanism of interaction with ARAs deemed to be clinically significant are shown in Table [4](#Tab4){ref-type="table"}. Table 1 in the Electronic Supplementary Material expands on each interaction, provides clinical data and references, and comments further on mitigation strategies.Table 4Substrates with a clinically meaningful gastric pH-dependent mechanism of interaction (*n* = 38)DrugAntacidH2RAPPIAcalabrutinibSeparate by 2 hTake 2 h before H2RA×AtazanavirTake 2 h before or 1 h after antacidHIV treatment-naïve patients: take 2 h before or 10 h after H2RA in those unable to tolerate ritonavir; patients receiving ritonavir should take H2RA simultaneously with atazanavir and food or atazanavir 10 h after H2RAHIV treatment-experienced patients: take H2RA simultaneously with atazanavir and food or atazanavir 10 h after H2RA×Can be administered with boosted atazanavir 12 h after PPI in patients that are treatment-naïve to atazanavirBisacodyl DRSeparate by at least 1 h----Bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride×× with cimetidine and other inhibitors of CYP✓BosutinibSeparate by minimum of 2 hSeparate by minimum of 2 h×Cefditoren pivoxil×××Cefpodoxime proxetilSeparate by 2 hSeparate by minimum of 2 hMonitorCefuroxime axetilTake 1 h before or 2 h after antacid××Dabigatran etexilate mesylateCanada: take 2 h before antacid; monitorUSA: ✓USA: ✓DasatinibSeparate by minimum of 2 h××DelaviradineSeparate by 1 h××DigoxinMonitor--MonitorEmtricitabine, rilpivirine hydrochloride, tenofovir disoproxil fumarate (Complera^®^)Take 4 h before or 2 h after antacidTake 4 h before or 12 h after H2RA×ErlotinibSeparate by a few hoursTake 2 h before or 10 h after H2RA×Ferrous sulfateSeparate as much as possible, monitor----GefitinibSeparate by 6 hSeparate by 6 h×If necessary, separate by 12 hHyoscyamineAdminister before meals and antacid after meals----Indinavir--MonitorMonitorItraconazoleSeparate by 2 h; consider administering with non-diet colaSeparate by 2 h; monitor; administer with non-diet colaSeparate by 2 h; monitor; administer with non-diet colaKetoconazoleTake 2 h before or 1 h after antacid; monitorMonitor; administer with non-diet colaMonitor; administer with non-diet colaLapatinibUSA: ✓ UK: ×USA: ✓ UK: ×USA: ✓ UK: ×Ledipasvir, sofosbuvir (Harvoni^®^)Separate by 4 hTime simultaneously or 12 h apartSimultaneously under fasting conditionsMefenamic acid×----Mesalamine×----Nelfinavir--Monitor×NeratinibTake 3 h after antacidTake 2 h before or 10 h after H2RA×NilotinibSeparate by 2 hTake 2 h before or 10 h after H2RA×Pazopanib×××PhenytoinDo not take at same time of day----Posaconazole oral suspension (Noxafil^®^)✓✓ for H2RA other than cimetidine; × for cimetidine×Raltegravir (Isentress^®^)× for aluminum and/or magnesium antacids; × for calcium carbonate for high-dose raltegravir; ✓ for raltegravir--✓RiociguatSeparate by 1 h--✓Risedronate sodium (Atelvia DR)×××Sofosbuvir, velpatasvir (Epclusa^®^)Separate by 4 hTime simultaneously or 12 h apart×If necessary, take with food and 4 h before PPIMedications were identified via searches and screens of the PDR3D: Reed Tech Navigator™, University of Washington Drug--Drug Interaction Database (DIDB), and DailyMed databases as detailed in Sect. [4.1](#Sec31){ref-type="sec"}*CYP* cytochrome P450, *DR* delayed release, *H2RA* histamine H~2~ receptor antagonist, *PPI* proton pump inhibitor, ✓ coadministration shows no interaction, × coadministration not recommended, -- no information available

Table [5](#Tab5){ref-type="table"} lists medications that interact with ARAs based on a non-gastric pH-based mechanism, including chelation, CYP-mediated interactions, transporter-mediated interactions, and urine alkalization. Table 2 in the Electronic Supplementary Material provides indepth information on the mechanism of interaction, clinical data, mitigation strategies, and references.Table 5Medications with a clinically meaningful other mechanism of interaction, not gastric pH-based (*n* = 83)Victim drugARA/perpetratorMechanism of interactionAnti-infectives AzithromycinMagnesium-/aluminum-containing antacidsLikely chelation BictegravirAntacidsLikely chelation ChloroquineCimetidineInhibition of CYP CiprofloxacinMagnesium-/aluminum-containing antacidsChelation DolutegravirCalcium-based antacidsChelation DoxycyclineMagnesium-/aluminum-/calcium-containing antacids, PPIsLikely chelation GemifloxacinMagnesium-/aluminum-containing antacidsChelation LevofloxacinMagnesium-/aluminum-containing antacidsChelation MethenamineAntacidsUrine alkalization MinocyclineMagnesium-/aluminum-/calcium-containing antacidsLikely chelation MoxifloxacinMagnesium-/aluminum-containing antacidsChelation NorfloxacinCation-containing antacids^a^Chelation Quinine sulfateAntacids/H2RAsChelation/inhibition of CYP3A4 TetracyclineMagnesium-/aluminum-/calcium-containing antacidsLikely chelationCNS agents AlprazolamCimetidineInhibition of CYP3A4 CarbamazepineCimetidineLikely inhibition of CYP3A4 CitalopramCimetidine/omeprazoleLikely inhibition of CYP/inhibition of CYP2C19 ClobazamOmeprazoleInhibition of CYP2C19 ClozapineCimetidineInhibition of CYP3A4 DalfampridineCimetidineInhibition of OCT2 DesipramineCimetidineLikely inhibition of CYP DoxepinCimetidineLikely inhibition of CYP EscitalopramCimetidine/proton pump inhibitorsLikely inhibition of CYP/inhibition of CYP2C19 GabapentinAntacid containing aluminum and magnesiumPossible chelation LisdexamfetamineSodium bicarbonateUrine alkalization MemantineAntacids (sodium bicarbonate)Urine alkalization MirtazapineCimetidineLikely inhibition of CYP ParoxetineCimetidineLikely inhibition of CYP PramipexoleCimetidineInhibition of OCT2 SulpirideAntacidsUnknown TizanidineCimetidineInhibition of CYP1A2 ZolmitriptanCimetidineLikely inhibition of CYPCardiovascular agents CaptoprilAntacidsUnknown CarvedilolCimetidineLikely inhibition of CYP DiltiazemCimetidineLikely inhibition of CYP3A4 DofetilideCimetidineInhibition of renal tubular secretion FelodipineCimetidineInhibition of CYP3A4 FosinoprilAntacidsUnknown NifedipineCimetidineInhibition of CYP NimodipineCimetidineInhibition of CYP3A4 NisoldipineCimetidineLikely inhibition of CYP3A4 NitrendipineCimetidineLikely inhibition of CYP PindololCimetidineLikely inhibition of CYP or inhibition of renal clearance ProcainamideCimetidineLikely inhibition of renal tubular secretion PropafenoneCimetidineLikely inhibition of CYP QuinidineCimetidineLikely inhibition of CYP3A4 RosuvastatinAntacidsPossible chelation SotalolAluminum- and/or magnesium-containing antacidsLikely chelation VerapamilCimetidineLikely inhibition of CYP3A4Immune suppressant agents CyclosporineH2RAsUnknown Mycophenolate mofetilAntacids with magnesium and/or aluminum hydroxideChelation Mycophenolic acidAntacids with magnesium and/or aluminum hydroxideChelation TacrolimusProton pump inhibitorsLikely inhibition of CYP3A4Blood-modifying agents AcenocoumarolCimetidineInhibition of CYP CilostazolOmeprazoleInhibition of CYP2C19 ClopidogrelProton pump inhibitors (esomeprazole, omeprazole)Inhibition of CYP2C19 EltrombopagCation-containing antacids^a^Chelation WarfarinCimetidineInhibition of hydroxylation in the liverMetal chelators DeferasiroxAluminum-containing antacidsChelation DeferiproneAntacidsChelation TrientineAntacidsMetal binding/chelationAnti-diabetic agents GlimepirideH2RAs (cimetidine, famotidine, nizatidine, ranitidine)Inhibition of metabolism and/or renal transport GlipizideH2RAs (cimetidine, famotidine, nizatidine, ranitidine)Inhibition of metabolism and/or renal transport MetforminCimetidineLikely inhibition of OCT2 TolbutamideCimetidineInhibition of metabolism and/or renal transportBisphosphonate AlendronateAntacidsLikely chelationAntirheumatic PenicillamineAntacidsLikely chelationChemotherapy 5-FluorouracilCimetidineLikely a combination of inhibition of metabolism and decreased liver blood flowExchange resin Sodium polystyrene sulfonateAntacidsLikely chelationGastrointestinal agents AlosetronCimetidineInhibition of CYP1A2Respiratory agents RoflumilastCimetidineInhibition of CYP3A4Urinary agents TamsulosinCimetidineInhibition of CYP3A4 Lanthanum carbonateAntacidsUnclear, possible chelationCholinergic agonist VareniclineH2RAs (cimetidine, famotidine, nizatidine, ranitidine)Possible inhibition of OCT2Medications were identified via searches and screens of the PDR3D: Reed Tech Navigator™, University of Washington Drug--Drug Interaction Database (DIDB), and DailyMed databases as detailed in Sect. [4.1](#Sec31){ref-type="sec"}*ARA* acid-reducing agent, *CNS* central nervous system, *CYP* cytochrome P450, *H2RA* histamine H~2~ receptor antagonist, *OCT2* organic cation transporter 2^a^It is suspected that 'cation-containing antacids' refer to polyvalent cations and not sodium bicarbonate when the mechanism of interaction is chelation

Table [6](#Tab6){ref-type="table"} shows medications with no clinically meaningful interaction with ARAs. Table 3 in the Electronic Supplementary Material provides supportive clinical data and references for these medications to support their use with ARAs without therapy change. All medications shown in Table [6](#Tab6){ref-type="table"} (and Table 3 in the Electronic Supplementary Material) have clinical data supporting lack of a clinically meaningful interaction with a designated ARA agent. Dependent on study design, it can reasonably be concluded that most of these mediations do not exhibit any gastric pH-dependent interaction.Table 6Medications with no clinically meaningful interaction with one or more acid-reducing agents (*n* = 109)AcitretinDonepezilLisdexamfetamineSertindoleAlectinibDronedaroneLopinavir and ritonavir (Kaletra^®^)SildenafilAmbrisentanDuloxetineLosartanSodium oxybateAmlodipineEfavirenzMeloxicamSorafenibAripiprazoleElbasvir and grazoprevir (Zepatier^®^)MetronidazoleSulfasalazineAsenapineEliglustatMoexiprilSulindacAspirinEprosartanNaproxen DRTapentadolAspirin/extended-release dipyridamole (Aggrenox^®^)EtravirineNebivololTelithromycinAxitinibEzetimibeNevirapineTemozolomideAzacitidineFamciclovirNifedipineTopotecanBetrixabanFebuxostatNintedanibTramadolBoceprevirFenofibric acidObeticholic acidTrandolaprilBortezomibFenoprofenOsimertinibUlipristal acetateBrexpiprazoleFluconazoleOxcarbazepineValacyclovirCabozantinibFluvastatinPalbociclibValproic acidCarvedilolFosamprenavirParicalcitolValsartanCephalexinGabapentinPioglitazoneVandetanibCeritinibGabapentin enacarbilPiroxicamVenlafaxineCobimetinibGarenoxacinPonatinibVilazodoneCrizotinibGlecaprevir/pibrentasvir (Mavyret™)Posaconazole delayed release capsulesVismodegibDabigatran etexilate mesylateGlimepiridePrasugrelVorapaxarDanoprevirImatinibPropranololVoriconazoleDapsoneIndinavirRaloxifeneZolpidemDarunavirIsavuconazonium sulfateRamelteonDiazepamIsoniazidRepaglinideDiclofenacItraconazole oral suspensionRisperidoneDigoxinLamotrigineRivaroxabanDivalproexLetrozoleSaxagliptinMedications were identified via searches and screens of the PDR3D: Reed Tech Navigator™, University of Washington Drug--Drug Interaction Database (DIDB), and DailyMed databases as detailed in Sect. [4.1](#Sec31){ref-type="sec"}*DR* delayed release

Potential Strategies to Mitigate Gastric Acid-Reducing Drug--Drug Interactions {#Sec33}
==============================================================================

Figure [2](#Fig2){ref-type="fig"} provides a decision-making sequence that prescribers and pharmacists can use to navigate through an interaction posed with an ARA. When an interaction is identified, the prescriber or pharmacist can choose to either change the ARA product or change the substrate medication. For example, changes would include either spacing of dosing in time, changing the dose, or selecting an alternative agent. When choosing to change the ARA, options include using a mitigation strategy or referring to Table [1](#Tab1){ref-type="table"} to select an alternative ARA. Table [1](#Tab1){ref-type="table"} shows the interaction profile of each ARA, and so selection of a non-interacting ARA would be made. When choosing to change the substrate medication, options include selecting an agent from a specific table depending on the mechanism of interaction. Strategies for both are shown for each mechanism of interaction.Fig. 2Decision-making tree for selecting a mitigation strategy. *ARA* acid-reducing agent, *CYP* cytochrome P450, *H2RA* histamine H~2~ receptor antagonist, *PPI* proton pump inhibitor

Discussion {#Sec34}
==========

Current resources available permit identification of medications that may interact with ARAs; however, reference to multiple sources is required for a comprehensive examination, which becomes challenging in clinical practice. A single resource of DDIs with ARAs may support prescribers and pharmacists in avoiding or mitigating adverse drug combinations in patients undergoing ARA treatment. In this comprehensive review, 121 individual medications were found to clinically meaningfully interact with ARAs. Thirty-eight medications were identified to have a mechanism of interaction that was gastric pH dependent, and 83 medications were found to interact with ARAs with a non-gastric pH-mediated interaction (CYP/transporter/chelation/urine alkalization).

This review identified the mechanisms underlying DDIs, which allowed for the proposal of mitigation strategies. While mitigation strategies for introducing an ARA (perpetrator) and a substrate medication together are described in this review, it is also important to re-evaluate therapy changes when ARA (perpetrator) doses are decreased or stopped. For some medications, mitigation strategies recommended in prescribing information when H2RAs are perpetrators of a clinically meaningful gastric pH-dependent interaction are often inconsistent and sometimes debatable based on their pharmacodynamic properties. H2RA activity can persist for up to 12 h, with peak acid suppression occurring around 2 h. The prescribing information of some medications, such as bosutinib, indicates separation by 2 h before or after the H2RA. Although administering a substrate medication 2 h before an H2RA is appropriate, administering the substrate medication 2 h after the H2RA can be problematic because this is the time of the peak gastric acid raising effect. Waiting 10--12 h after an H2RA has been administered would strongly suggest mitigation of a gastric pH-dependent interaction based on the minimal pharmacodynamic effects of H2RAs at this time.

Specifically for chelation-based interactions, clinical data for substrate medications were often extrapolated to include other agents in the class or derivatives of the substrate medication. Although the clinical study may not have used the exact substrate medication and ARA combination, health authorities or manufacturers believed that alternative agents in the same class or substrate medication derivatives have potential for similar DDIs. For example, a common class of anti-infective medications are fluoroquinolones. Most antacids are known to chelate with fluoroquinolones; not all fluoroquinolones have been studied with antacids, but data for ciprofloxacin have been applied to other agents in the class, such as trovafloxacin, because of the similar chemistry prone to chelation among these agents.

Because gastric pH elevation is a characteristic shared among all three classes of ARAs, if no clinically meaningful gastric pH-mediated interaction is observed with one ARA, it is highly unlikely that no gastric pH-mediated interaction will be observed with any ARA. Similarly, if a clinically meaningful gastric pH-mediated interaction is observed with one ARA, it is highly likely that a gastric pH-mediated interaction will be observed with all ARAs. This allows for extrapolation of findings to different ARAs based on gastric pH alone. Because of individual characteristics of ARAs (antacids, H2RAs, PPIs), non-gastric pH-and chelation-based interactions, such as CYP, transporter, and urine alkalization, cannot be extrapolated between ARAs.

Interestingly, 109 medications were found to not have any clinically meaningful interaction with ARAs, suggesting that clinical DDI studies may have been conducted unnecessarily. It may be possible to identify drugs likely or not likely to have ARA-mediated drug interactions from their physicochemical characteristics, which would reduce the need for clinical gastric pH-mediated DDI studies. This also indicates the potential utility of a health authority guidance on this topic describing when a clinical study is, or is not, necessary.

Limitations of this review are that the search strategy was not replicated by a second individual, the risk for incomplete retrieval of interactions via the search strategy used, and that any additional information available after 1 August 2018 was not captured. The search strategy did not specifically include the names of the potassium-competitive acid pump antagonists revaprazan \[[@CR43]\] and vonoprazan fumarate \[[@CR44]\], which are approved in South Korea and Japan, respectively. Additionally, these drugs were not identified using the broad search terms, likely due to the limited number of countries in which they are approved.

Conclusions {#Sec38}
===========

This comprehensive review of DDIs using ARAs as a perpetrator will potentially aid in the treatment of patients receiving polypharmacy, permit avoidance of DDIs that would otherwise affect patient care, and save time for prescribers and pharmacists. Additionally, an effort was made to capture various mitigation strategies that were recommended by different health authorities (e.g., those in Canada and the European Union) to better apply this review outside of the USA.
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Below is the link to the electronic supplementary material. Supplementary material 1 (PDF 621 kb)
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